Female Sexual Dysfunction Clinical Trial
Official title:
An Open-label, Single and Multiple Application of Intranasal Testosterone Gel (TBS-2) in Healthy Premenopausal Female Subjects at Three Dose Levels
Verified date | October 2019 |
Source | Acerus Pharmaceuticals Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study was to assess the bioavailability of total testosterone through
pharmacokinetic profiles obtained following (a) single administration of three doses of TBS-2
b) multiple administration TBS-2.
In addition, assessing the bioavailability of free testosterone, dihydrotestosterone, SHBG
and estradiol through pharmacokinetic profiles was also conducted.
Status | Completed |
Enrollment | 24 |
Est. completion date | February 2012 |
Est. primary completion date | January 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 18 Years to 40 Years |
Eligibility |
Inclusion Criteria - Subjects having regular menstrual cycles between 26-32 days. - Women of childbearing potential must agree to use one of the following reliable birth control methods prior to the study, during the study and up until one month after the end of the study: - Surgically sterile - Intrauterine device in place for at least 3 months prior to study initiation - Barrier method (condom with spermicidal agent use by partner) - Abstinence - Negative for drugs of abuse, hepatitis B-surface antigen, hepatitis C, HIV, and pregnancy (serum ß-HCG). - Body Mass Index greater than or equal to 18.5 kg/m² and less than or equal to 35 kg/m². - Subjects with a normal ENT exam. - Subjects with normal TSH values. - No clinically significant findings in the physical examination, 12-lead ECG and vital signs - Normal thyroid function. Physiological prolactin concentration. - All clinical laboratory test values within the acceptable ranges (any clinically significant findings will require investigator/sponsor approval) - Able to understand and provide written informed consent. - Availability of the subject for the entire study period and willingness of the subject to adhere to protocol requirements, as evidenced by a signed ICF Exclusion Criteria - Known history of hypersensitivity to Testosterone (e.g. Intrinsa patch) and/or related drugs. - Known history of polycystic ovarian syndrome. - Known history or presence of cardiac, pulmonary, gastrointestinal, endocrine, musculoskeletal, neurological, psychiatric, hematological, reproductive, liver or kidney disease, unless judged not clinically significant by the Principal Investigator or medical designate. - Presence of or known history of Estrogen-responsive tumors such as breast cancer and /or history of any cancer, excluding basal cell carcinoma. - Known history of frequent clinically significant acne. - Known history of hirsutism - History of nasal surgery, specifically turbinoplasty, septoplasty, rhinoplasty, "nose job", or sinus surgery. - Prior nasal fractures. - Active allergies, such as rhinitis, rhinorrhea, and nasal congestion. - Mucosal inflammatory disorders, specifically pemphigus, and Sjogren's syndrome. - Sinus disease, specifically acute sinusitis, chronic sinusitis, or allergic fungal sinusitis. - History of nasal disorders or sleep apnea. - Use of any form of intra-nasal medication delivery, specifically nasal corticosteroids and oxymetazoline containing nasal sprays - History of Hepatitis B, a positive test for Hepatitis B surface antigen, a history of Hepatitis C, a positive test for Hepatitis C antibody, a history of HIV infection or demonstration of HIV antibodies. - Any history of severe allergic reaction (including drugs, food, insect bites, environmental allergens or any condition known to interfere with the absorption, distribution, metabolism or excretion of drugs. - Any history of drug abuse or alcohol abuse as per DSM-IV criteria within 6 months of study drug administration. - Current treatment with any hormone replacement therapy within previous 12 months, treatment with drugs which interfere with metabolism of Testosterone within 30 days of study drug administration and/or any other prescription medications. Difficulty in abstaining from OTC medication for the duration of study. - Use of oral, transdermal and implant contraceptives within 30 days prior to drug administration or a depot contraceptives injection within one year prior to drug administration. - Evidence of pregnancy or lactation. - Subjects who are breast feeding or have breast fed within the last six (6) months prior to the Screening Visit. - Administration of another investigational drug within 30 days prior to study medication administration. - Blood donation within 56 days prior to study medication administration. - Any participation as a plasma donor in a plasmapheresis program within seven days preceding screening in this study. - Intolerance to venipuncture. - History of abnormal bleeding tendencies or thrombophlebitis unrelated to venipuncture or intravenous cannulation. - History of Deep Venous Thrombosis or coagulation disorders. |
Country | Name | City | State |
---|---|---|---|
United States | Premier Research International LLC | Austin | Texas |
Lead Sponsor | Collaborator |
---|---|
Acerus Pharmaceuticals Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bioavailability (AUC0-t) of Total Testosterone Through Pharmacokinetic (PK) Profiles | Area under the concentration time curve from time zero to the last measurable concentration time point (AUC0-t) for single dose and AUCtau shown for multiple dose. | Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing | |
Primary | Bioavailability (Cmax) of Total Testosterone Through Pharmacokinetic Profiles | Cmax - maximum concentration of total testosterone observed after dosing of TBS-2 | Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing | |
Primary | Medium Dose TBS-2 Multiple Dose Average Steady-state Concentration (Cavg) of Total Testosterone | -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 24, 32, 40, 48h after Day 3 dosing | ||
Secondary | Area Under the Plasma Concentration Versus Time Curve (AUC) for Dihydrotestosterone Following TBS-2 | AUCt shown for single dose and AUCtau for multiple dose. | Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing | |
Secondary | Area Under the Plasma Concentration Versus Time Curve (AUC) for Estradiol Following TBS-2 | AUCt shown for single dose and AUCtau for multiple dose. | Based on blood samples collected -0.25, 0.25, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 16, 20, 23.5h relative to dosing |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05806424 -
Investigation of Awareness Levels of Women Living in Turkey About Kegel Exercises and Pelvic Floor Muscles
|
||
Completed |
NCT06060691 -
the Ameliorating Effects of Antioxidant Gel on Female Arousal Disorder and Sexual Dysfunction
|
Phase 1 | |
Recruiting |
NCT04419961 -
Sexual Dysfunction and an Educational Program to Improve the Quality of Sexual Function in Vietnamese Pregnant Women in First Trimester
|
N/A | |
Completed |
NCT04122703 -
Trial of Tibial Nerve Stimulation for Treating Sexual Dysfunction
|
N/A | |
Recruiting |
NCT03498443 -
Effect of Pelvic Organ Prolapse Surgeries on Female Sexual Function in Egyptian Women
|
||
Completed |
NCT03232801 -
A Mindfulness-based Intervention for Older Women With Low Sexual Desire
|
N/A | |
Completed |
NCT04124640 -
Observational Study in Real Life to Describe the Libicare® Effectiveness in Female Sexual Dysfunction.
|
||
Completed |
NCT00995072 -
Comparative Effects of Nebivolol and Metoprolol on Female Sexual Function
|
N/A | |
Active, not recruiting |
NCT05168371 -
Cognitive-Behavioural & Mindfulness-Based Online Programs for Female Sexual Dysfunction
|
N/A | |
Completed |
NCT04384172 -
Effect of Peripheral Neuromodulation on Vaginal Blood Flow
|
N/A | |
Recruiting |
NCT06237166 -
Evaluation of an Online Intervention for Female Sexual Dysfunction
|
N/A | |
Completed |
NCT03463707 -
BP101 for Adults With Female Sexual Dysfunction
|
Phase 3 | |
Recruiting |
NCT01078077 -
The Impact of a Topical Vasodilating Cream on Female Sexual Experience
|
N/A | |
Completed |
NCT01724658 -
Effectiveness of Testosterone Undecanoate to Improve Sexual Function in Postmenopausal Women
|
Phase 2 | |
Completed |
NCT02229721 -
Effect of Chronic Intranasal Oxytocin Administration on Sexual Function in Pre- and Postmenopausal Women
|
Phase 2 | |
Completed |
NCT00479570 -
Study To Investigate Effect Of A New Drug (PF-00446687) In Post-Menopausal Women Who Suffer From Sexual Dysfunction.
|
Phase 2 | |
Not yet recruiting |
NCT06116045 -
Evaluation of the Efficacy, Safety and Tolerability of BZ371A in Women With Sexual Arousal Disorder
|
Phase 2 | |
Withdrawn |
NCT02862184 -
Female Sexual Dysfunction, Risks and Outcomes (FSFI)
|
N/A | |
Completed |
NCT01195701 -
Clitoral Location in Relation to Sexual Function Using Pelvic Imaging
|
N/A | |
Completed |
NCT04484753 -
Validation of iPelvis App for Female Pelvic Floor Dysfunction
|
N/A |